102940 — Kolon Life Science Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapMomentum Trap

Annual income statement for Kolon Life Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	129,413	165,485	161,584	124,639	161,387
Cost of Revenue
Gross Profit	18,896	37,202	37,139	12,411	16,868
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	156,440	165,939	161,823	151,867	219,550
Operating Profit	-27,027	-454	-239	-27,228	-58,164
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-43,195	-4,011	4,124	-33,598	-93,086
Provision for Income Taxes
Net Income After Taxes	-43,195	-1,375	4,016	-33,599	-93,086
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-43,195	-1,375	2,133	-30,726	-93,086
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-43,195	-1,375	2,133	-30,726	-93,086
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-3,998	122	491	-2,765	-4,688
Dividends per Share